Fig. 1: Overview of the ASTUTE framework. | npj Precision Oncology

Fig. 1: Overview of the ASTUTE framework.

From: Integrative analysis of KEAP1/NFE2L2 alterations across 3600+ tumors reveals an NRF2 expression signature as a prognostic biomarker in cancer

Fig. 1

In A–C we illustrate how our framework can efficiently integrate mutations with gene expression data to perform the extraction of dysregulated genes associated with KEAP1 or NFE2L2 mutations in distinct NSCLC datasets. In D we highlight the consistent association of the identified genes with the NRF2 pathway. In E we show that ASTUTE can stratify patients based on the identified expression signatures, thus enhancing the prognostic insights returned by the approach. Finally, in F we showcase that ASTUTE could determine a set of genes consistently dysregulated across in NSCLC andother cancer types, emphasizing their role in prognosis at the pan-cancer level. ASTUTE’s multidimensional analysis enables a deeper understanding of genotype-phenotype associations in cancer.

Back to article page